ArticleClinical and translational gastroenterology2020
Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.
Article in Clinical and translational gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Transcriptomic Profiling of Laser Capture Microdissected FFPE Esophageal Tissues Identifies Candidate Genes and Pathways Associated with Esophageal Adenocarcinoma.International journal of molecular sciences · 2026Article
- Metabolome restructuring reveals distinct virocell infection strategies in bacteriophage-host interaction.ISME communications · 2026Article
- Nonendoscopic Screening for Barrett's Esophagus: Current Methods, Evidence, and Future Directions.Gastro hep advances · 2026Review
- MiRNA expression analysis from circulating exosomes in Barrett's esophagus patients with visceral obesity.Scientific reports · 2025Article
- New Approaches to Screening for Barrett Esophagus.Gastroenterology & hepatology · 2025Article
- Liquid biopsy to identify Barrett's oesophagus, dysplasia and oesophageal adenocarcinoma: theGut · 2025Article
- Cultivar and Harvest Time of Almonds Affect Their Antioxidant and Nutritional Profile through Gut Microbiota Modifications.Antioxidants (Basel, Switzerland) · 2024Article
- Role of exosomes in metastasis and therapeutic resistance in esophageal cancer.World journal of gastroenterology · 2023Review
- MicroRNA expression associated with low-grade cervical intraepithelial neoplasia outcomes.Journal of cancer research and clinical oncology · 2023Article
- New Techniques to Screen for Barrett Esophagus.Gastroenterology & hepatology · 2023Article
- Correlation analysis and prognostic value of miR-29a-3p expression and CYP2C19 genotypes in exfoliated cells from tongue coating of patients with gastroesophageal reflux disease.Genes & genomics · 2023Article
- Expanding beyond endoscopy: A review of non-invasive modalities in Barrett's esophagus screening and surveillance.World journal of gastroenterology · 2022Review
- Article
- Salivary biomarkers and esophageal disorders.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2022Review
- Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.Cancer medicine · 2022Review
- Alteration of protein expression and spliceosome pathway activity during Barrett's carcinogenesis.Journal of gastroenterology · 2021Article
- Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence.Cancers · 2021Review
- Screening for Barrett's Oesophagus: Are We Ready for it?Current treatment options in gastroenterology · 2021Review
- Extracellular miRNAs for the Management of Barrett's Esophagus and Esophageal Adenocarcinoma: A Systematic Review.Journal of clinical medicine · 2020Review
- A narrative review of Barrett's esophagus in 2020, molecular and clinical update.Annals of translational medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBarrett's esophagus (BE) is the precursor lesion and a major risk factor for esophageal adenocarcinoma (EAC). Although patients with BE undergo routine endoscopic surveillance, current screening methodologies have proven ineffective at identifying individuals at risk of EAC. Since microRNAs (miRNAs) have potential diagnostic and prognostic value as disease biomarkers, we sought to identify an miRNA signature of BE and EAC.
methodsHigh-throughput sequencing of miRNAs was performed on serum and tissue biopsies from 31 patients identified either as normal, gastroesophageal reflux disease (GERD), BE, BE with low-grade dysplasia (LGD), or EAC. Logistic regression modeling of miRNA profiles with Lasso regularization was used to identify discriminating miRNA. Quantitative reverse transcription polymerase chain reaction was used to validate changes in miRNA expression using 46 formalin-fixed, paraffin-embedded specimens obtained from normal, GERD, BE, BE with LGD or HGD, and EAC subjects.
resultsA 3-class predictive model was able to classify tissue samples into normal, GERD/BE, or LGD/EAC classes with an accuracy of 80%. Sixteen miRNAs were identified that predicted 1 of the 3 classes. Our analysis confirmed previous reports indicating that miR-29c-3p and miR-193b-5p expressions are altered in BE and EAC and identified miR-4485-5p as a novel biomarker of esophageal dysplasia. Quantitative reverse transcription polymerase chain reaction validated 11 of 16 discriminating miRNAs. DISCUSSION: Our data provide an miRNA signature of normal, precancerous, and cancerous tissue that may stratify patients at risk of progressing to EAC. We found that serum miRNAs have a limited ability to distinguish between disease states, thus limiting their potential utility in early disease detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.